Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X FTSE Southeast Asia ETF (ASEA) vs Pfizer Inc (PFE) Price & Performance

Global X FTSE Southeast Asia ETF
Pfizer Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X FTSE Southeast Asia ETF vs Pfizer Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Pfizer Inc trades at $24.25 (market cap $137.76B). The key difference: Pfizer Inc pays a 7.12% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.

ASEAPFE
Sector
Sector/ThematicHealth
52-Week High
$20.65$28.56
52-Week Low
$16.31$23.29
Market Cap
$137.76B
Volume
29,869,932
Enterprise Value
$188.41B
Dividend Yield
7.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X FTSE Southeast Asia ETF

ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.

The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.

Pfizer Inc

Pfizer (PFE) trades at $24.17, down 0.33% on the day, with a bearish technical signal and neutral oscillators. The company maintains solid fundamentals with a P/E of 18.45, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline developments in obesity and oncology, with a $0.43 quarterly dividend providing income stability.

The outlook remains mixed: analyst consensus targets $27.63 (14% upside) but technicals suggest near-term pressure. Key risks include patent cliffs and competitive threats, while institutional sentiment leans hold. Valuation appears reasonable relative to cash flow generation, making PFE a defensive play with moderate growth potential amid ongoing pipeline execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.

Read more on ASEA

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE